Introduction
The insulin-like growth factor 1 (IGF-1) axis is one of the most important endocrine and paracrine signaling systems in mammalian biology, regulating cell growth, differentiation, protein synthesis, and metabolism throughout the body. Understanding this axis provides essential context for research with IGF-1 LR3, IGF-1 DES, MGF, and PEG-MGF — all of which act through components of this system.
The GH-IGF-1 Endocrine Axis
The classic endocrine IGF-1 axis is regulated by growth hormone (GH) secreted from the pituitary gland. GH travels through the bloodstream to the liver, where it binds GH receptors and stimulates hepatic IGF-1 production. Circulating IGF-1 then acts throughout the body to mediate many of GH’s anabolic effects — muscle protein synthesis, bone growth, adipose tissue regulation, and metabolic effects on glucose and fat metabolism. This liver-derived circulating IGF-1 is the endocrine arm of the axis.
IGF-Binding Proteins (IGFBPs)
IGF-1 in plasma is not free — approximately 99% is bound to IGF-binding proteins (IGFBPs 1-6). These binding proteins serve as a circulating reservoir that prolongs IGF-1 half-life from minutes to hours, regulate bioavailability by controlling free IGF-1 concentration, and in some cases have independent biological effects through their own receptors. IGFBP-3 is the primary high-affinity binding protein in adult plasma, typically carrying IGF-1 and IGF-2 in a ternary complex with acid-labile subunit (ALS).
Why IGF-1 LR3 Bypasses IGFBPs
Native IGF-1 has high affinity for IGFBPs, limiting its free bioavailability. IGF-1 LR3 was engineered with an Arg3 substitution and N-terminal extension that dramatically reduce IGFBP binding affinity while preserving IGF-1R binding. The result is a research form of IGF-1 that behaves as if IGFBPs were absent — essentially all of the administered compound is bioavailable rather than sequestered. This makes IGF-1 LR3 a much more potent in vivo tool per mole administered than native IGF-1.
Local vs Systemic IGF-1 Signaling
Beyond the endocrine (liver-derived) IGF-1 axis, local IGF-1 production occurs in many tissues including muscle, bone, brain, and skin. Locally produced IGF-1 acts in an autocrine or paracrine manner — signaling within the producing tissue rather than traveling through the circulation. The splice variant MGF is specifically expressed locally in response to muscle mechanical loading, representing the first rapid repair signal in muscle tissue before systemic IGF-1 signaling is activated. IGF-1 DES is another locally-acting form with high IGFBP-independence.
IGF-1R: The Primary Receptor
The IGF-1 receptor (IGF-1R) is a receptor tyrosine kinase that, upon IGF-1 binding, autophosphorylates and recruits insulin receptor substrate (IRS) proteins. This activates two major downstream cascades: the PI3K-Akt-mTOR pathway (promoting protein synthesis, cell survival, and cell cycle progression) and the MAPK-ERK pathway (regulating cell proliferation and differentiation). mTOR activation is the primary connection between IGF-1 signaling and muscle protein synthesis — making IGF-1 axis research centrally relevant to muscle biology and sarcopenia research.
Conclusion
The IGF-1 axis encompasses endocrine GH-stimulated hepatic IGF-1 production, IGFBP-regulated bioavailability, local tissue IGF-1 splice variant signaling (MGF, IGF-1 DES), and IGF-1R-mediated PI3K/Akt and MAPK signaling. Understanding this complete picture is essential for interpreting research with the multiple IGF-1 axis research tools including IGF-1 LR3, IGF-1 DES, MGF, and PEG-MGF.